MedPath

Genomics in Michigan Impacting Observation or Radiation

Not Applicable
Active, not recruiting
Conditions
Prostate Cancer
Registration Number
NCT02783950
Lead Sponsor
University of Michigan Rogel Cancer Center
Brief Summary

To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.

Detailed Description

This prospective, randomized trial will compare the receipt of adjuvant therapy for high-risk radical prostatectomy (RP) patients who undergo Decipher testing to those who do not. 350 subjects from within the statewide Michigan Urological Surgery Improvement Collaborative (MUSIC) will be randomized to either a Genomic Classifier (Decipher) or Usual-Care-Based (UC) strategy for a period of three months. If enrolled during the Genomic Classifier period, both subjects and their treating physician will be provided Decipher results and CAPRA-S scores. In the UC periods, CAPRA-S scores but not Decipher results will be provided.

The enrollment goal, initially and throughout the study, was to enroll 350 evaluable patients. During the study, the target accrual goal was raised to 550 patients to allow more flexibility among sites to achieve the enrollment goal of 350 evaluable patients.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Male
Target Recruitment
356
Inclusion Criteria
  • Prostate cancer patients who have undergone radical prostatectomy

  • PSA < 0.1 ng/ml at enrollment

  • At least one of the following:

    • pT3 (seminal vesicle invasion or extraprostatic extension), or
    • Positive surgical margins
  • Radical prostatectomy within one year of enrollment

Exclusion Criteria
  • Individuals who have any of the following will not be eligible to participate:

    • Have regional or distant metastatic disease
    • Received any radiation or hormone therapy (neo-adjuvant, adjuvant, or salvage)
    • Node positive

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of Participants That Receive Adjuvant Therapy (Radiation and/or Hormone Therapy)within 18 months of radical prostatectomy

Adjuvant will be defined as preceding biochemical recurrence (BCR) (i.e.: PSA ≥ 0.2 ng/ml) and within 18 months of radical prostatectomy.

Secondary Outcome Measures
NameTimeMethod
Michigan Urological Surgery Improvement Collaborative (MUSIC) Patient Reported Outcomes (PRO)Up to 24 months post radical prostatectomy

Composite Expanded Prostate Cancer Index Composite (EPIC)-26 domain scores for a) urinary irritative function, b) urinary incontinence, and c) sexual function will be measured at baseline and 24 months post-radical prostatectomy. Each of the 3 domains is scaled from 0-100 (higher is better).

Time (From Randomization) to Adjuvant Treatment AdministrationUp to 18 months post randomization

Adjuvant treatment (radiation and/or hormone) is defined as preceding BCR. BCR occurs when prostate specific antigen (PSA) ≥ 0.2 ng/ml.

Time (From Randomization) to Salvage Treatment AdministrationUp to 5 years post randomization

Salvage treatment (radiation and/or hormone therapy) is defined as either after BCR or \>18 months after surgery in the absence of documented BCR

Time (From Randomization) to Biochemical Recurrence (BCR)Up to 5 years post randomization

BCR is defined as PSA ≥ 0.2 ng/ml.

Time (From Randomization) to Metastatic Disease (Regional or Distant)Up to 5 years post randomization

Metastasis is determined based on CT, MRI, bone scan, and/or positron emission tomography (PET) scan

Trial Locations

Locations (13)

University of Michigan Hospital and Health Systems

🇺🇸

Ann Arbor, Michigan, United States

Wayne State University/Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Urologic Consultants

🇺🇸

Grand Rapids, Michigan, United States

Urology Associates of Grand Rapids

🇺🇸

Grand Rapids, Michigan, United States

Michigan Urological Clinic

🇺🇸

Grand Rapids, Michigan, United States

Spectrum Health Medical Group- Urology

🇺🇸

Grand Rapids, Michigan, United States

Urology Surgeons, PC

🇺🇸

Grand Rapids, Michigan, United States

Comprehensive Medical Center, PLLC

🇺🇸

Royal Oak, Michigan, United States

Tri-City Urology

🇺🇸

Saginaw, Michigan, United States

Scroll for more (3 remaining)
University of Michigan Hospital and Health Systems
🇺🇸Ann Arbor, Michigan, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.